IQVIA Holdings Inc. (IQV) EV/EBIT Ratio: 13.56x
Is IQVIA Holdings Inc.’s EV/EBIT ratio high or low?
IQVIA Holdings Inc.'s EV/EBIT ratio of 13.56x is 55% below its 5-year average of 30.04x, near the low end of its 5-year range (11.99x–66.49x).
The EV/EBIT ratio for IQVIA Holdings Inc. (IQV) is 13.56x as of Wednesday, June 10, 2026. It is below its 12-month average by 33.52% (20.40x).
IQV EV/EBIT Ratio Chart
IQV Average EV/EBIT Ratio Chart
IQV Current vs Average EV/EBIT Ratio Chart
IQV EV/EBIT Ratio Metrics
EV/EBIT RATIO
13.56x
EV/EBIT RATIO AVG TTM
20.40x
EV/EBIT RATIO AVG 3Y
24.04x
EV/EBIT RATIO AVG 5Y
30.04x
EV/EBIT RATIO AVG 10Y
38.18x
EV/EBIT RATIO AVG 15Y
33.11x
EV/EBIT RATIO AVG 20Y
33.11x
CURRENT VS TTM AVG
-33.52%
CURRENT VS 3Y AVG
-43.59%
CURRENT VS 5Y AVG
-54.86%
CURRENT VS 10Y AVG
-64.48%
CURRENT VS 15Y AVG
-59.05%
CURRENT VS 20Y AVG
-59.05%
IQV Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | — | 13.56x | 20.40x | 24.04x | 30.04x |
| Centene Corporation (CNC) | $31.94B | N/A | 10.37x | 16.91x | 20.65x |
| DexCom, Inc. (DXCM) | $29.24B | 29.06x | 38.74x | 65.30x | 101.94x |
| Biogen Inc. (BIIB) | $29.00B | 20.98x | 13.26x | 14.80x | 15.73x |
| Veeva Systems Inc. (VEEV) | $27.37B | 27.25x | 45.67x | 60.73x | 66.40x |
| Zoetis Inc. (ZTS) | $34.20B | 11.68x | 17.91x | 24.03x | 27.39x |
| Waters Corporation (WAT) | $23.83B | 54.60x | 27.55x | 26.51x | 26.24x |
| Agilent Technologies, Inc. (A) | $38.26B | 25.74x | 26.26x | 27.11x | 28.93x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.94x | 26.09x | 26.29x | 29.26x |
| BioNTech SE (BNTX) | $21.81B | N/A | 4.91x | 5.85x | 5.85x |
IQVIA Holdings Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The EV/EBIT ratio for IQV stock is 13.56x.
- Is IQVIA Holdings Inc.'s EV/EBIT ratio high or low?
- IQVIA Holdings Inc.'s EV/EBIT ratio of 13.56x is 55% below its 5-year average of 30.04x, near the low end of its 5-year range (11.99x–66.49x).
- What is the TTM average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The TTM average EV/EBIT ratio for IQV stock is 20.40x.
- What is the 3Y average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The 3Y average EV/EBIT ratio for IQV stock is 24.04x.
- What is the 5Y average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The 5Y average EV/EBIT ratio for IQV stock is 30.04x.
- What is the 10Y average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The 10Y average EV/EBIT ratio for IQV stock is 38.18x.
- What is the 15Y average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The 15Y average EV/EBIT ratio for IQV stock is 33.11x.
- What is the 20Y average EV/EBIT ratio for IQVIA Holdings Inc. (IQV)?
- The 20Y average EV/EBIT ratio for IQV stock is 33.11x.
IQVIA Holdings Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-10 | 13.56x |
| 2026-06-09 | 13.78x |
| 2026-06-08 | 13.59x |
| 2026-06-05 | 13.57x |
| 2026-06-04 | 13.82x |
| 2026-06-03 | 13.47x |
| 2026-06-02 | 13.36x |
| 2026-06-01 | 13.82x |
| 2026-05-29 | 13.48x |
| 2026-05-28 | 13.40x |
| 2026-05-27 | 12.26x |
| 2026-05-26 | 11.99x |
| 2026-05-22 | 12.42x |
| 2026-05-21 | 12.43x |
| 2026-05-20 | 12.69x |
| 2026-05-19 | 12.81x |
| 2026-05-18 | 12.79x |
| 2026-05-15 | 12.51x |
| 2026-05-14 | 12.63x |
| 2026-05-13 | 12.75x |
| 2026-05-12 | 12.95x |
| 2026-05-11 | 12.84x |
| 2026-05-08 | 13.22x |
| 2026-05-07 | 13.22x |
| 2026-05-06 | 13.06x |
| 2026-05-05 | 13.05x |
| 2026-05-04 | 18.30x |
| 2026-05-01 | 18.07x |
| 2026-04-30 | 18.11x |
| 2026-04-29 | 17.98x |
| 2026-04-28 | 18.16x |
| 2026-04-27 | 18.52x |
| 2026-04-24 | 18.40x |
| 2026-04-23 | 18.28x |
| 2026-04-22 | 19.38x |
| 2026-04-21 | 19.41x |
| 2026-04-20 | 19.49x |
| 2026-04-17 | 19.47x |
| 2026-04-16 | 19.13x |
| 2026-04-15 | 19.59x |
| 2026-04-14 | 19.38x |
| 2026-04-13 | 19.13x |
| 2026-04-10 | 18.78x |
| 2026-04-09 | 18.91x |
| 2026-04-08 | 19.18x |
| 2026-04-07 | 19.03x |
| 2026-04-06 | 19.04x |
| 2026-04-02 | 19.23x |
| 2026-04-01 | 19.16x |
| 2026-03-31 | 19.02x |
| 2026-03-30 | 18.70x |
| 2026-03-27 | 18.52x |
| 2026-03-26 | 18.94x |
| 2026-03-25 | 18.66x |
| 2026-03-24 | 18.69x |
| 2026-03-23 | 18.76x |
| 2026-03-20 | 18.69x |
| 2026-03-19 | 18.72x |
| 2026-03-18 | 18.76x |
| 2026-03-17 | 18.87x |
| 2026-03-16 | 18.60x |
| 2026-03-13 | 18.59x |
| 2026-03-12 | 18.45x |
| 2026-03-11 | 19.10x |
| 2026-03-10 | 19.05x |
| 2026-03-09 | 19.63x |
| 2026-03-06 | 19.32x |
| 2026-03-05 | 19.62x |
| 2026-03-04 | 19.58x |
| 2026-03-03 | 19.28x |
| 2026-03-02 | 19.31x |
| 2026-02-27 | 19.65x |
| 2026-02-26 | 19.03x |
| 2026-02-25 | 18.38x |
| 2026-02-24 | 18.60x |
| 2026-02-23 | 18.41x |
| 2026-02-20 | 18.66x |
| 2026-02-19 | 18.94x |
| 2026-02-18 | 19.06x |
| 2026-02-17 | 18.57x |
| 2026-02-13 | 19.28x |
| 2026-02-12 | 19.43x |
| 2026-02-11 | 20.08x |
| 2026-02-10 | 20.50x |
| 2026-02-09 | 21.30x |
| 2026-02-06 | 20.89x |
| 2026-02-05 | 20.38x |
| 2026-02-04 | 22.08x |
| 2026-02-03 | 22.17x |
| 2026-02-02 | 24.34x |
| 2026-01-30 | 24.25x |
| 2026-01-29 | 24.68x |
| 2026-01-28 | 25.01x |
| 2026-01-27 | 25.11x |
| 2026-01-26 | 24.98x |
| 2026-01-23 | 24.66x |
| 2026-01-22 | 24.95x |
| 2026-01-21 | 25.14x |
| 2026-01-20 | 24.53x |
| 2026-01-16 | 24.84x |
| 2026-01-15 | 25.13x |
| 2026-01-14 | 25.13x |
| 2026-01-13 | 25.15x |
| 2026-01-12 | 25.09x |
| 2026-01-09 | 25.22x |
| 2026-01-08 | 25.28x |
| 2026-01-07 | 25.36x |
| 2026-01-06 | 25.07x |
| 2026-01-05 | 24.60x |
| 2026-01-02 | 23.88x |
| 2025-12-31 | 23.88x |
| 2025-12-30 | 24.06x |
| 2025-12-29 | 24.01x |
| 2025-12-26 | 24.00x |
| 2025-12-24 | 23.93x |
| 2025-12-23 | 23.86x |
| 2025-12-22 | 23.80x |
| 2025-12-19 | 23.51x |
| 2025-12-18 | 23.65x |
| 2025-12-17 | 23.57x |
| 2025-12-16 | 23.58x |
| 2025-12-15 | 23.74x |
| 2025-12-12 | 23.63x |
| 2025-12-11 | 23.92x |
| 2025-12-10 | 23.68x |
| 2025-12-09 | 23.30x |
| 2025-12-08 | 23.73x |
| 2025-12-05 | 23.91x |
| 2025-12-04 | 23.84x |
| 2025-12-03 | 24.02x |
| 2025-12-02 | 23.90x |
| 2025-12-01 | 24.12x |
| 2025-11-28 | 24.24x |
| 2025-11-26 | 24.38x |
| 2025-11-25 | 24.39x |
| 2025-11-24 | 24.10x |
| 2025-11-21 | 23.84x |
| 2025-11-20 | 23.23x |
| 2025-11-19 | 23.25x |
| 2025-11-18 | 23.24x |
| 2025-11-17 | 23.15x |
| 2025-11-14 | 23.50x |
| 2025-11-13 | 23.73x |
| 2025-11-12 | 23.52x |
| 2025-11-11 | 23.34x |
| 2025-11-10 | 22.91x |
| 2025-11-07 | 22.70x |
| 2025-11-06 | 22.73x |
| 2025-11-05 | 22.67x |
| 2025-11-04 | 22.74x |
| 2025-11-03 | 22.97x |
| 2025-10-31 | 23.17x |
| 2025-10-30 | 23.17x |
| 2025-10-29 | 23.28x |
| 2025-10-28 | 23.31x |
| 2025-10-27 | 23.56x |
| 2025-10-24 | 23.81x |
| 2025-10-23 | 23.76x |
| 2025-10-22 | 23.60x |
| 2025-10-21 | 23.66x |
| 2025-10-20 | 23.14x |
| 2025-10-17 | 22.54x |
| 2025-10-16 | 22.63x |
| 2025-10-15 | 22.42x |
| 2025-10-14 | 22.56x |
| 2025-10-13 | 22.48x |
| 2025-10-10 | 22.03x |
| 2025-10-09 | 22.42x |
| 2025-10-08 | 22.22x |
| 2025-10-07 | 22.25x |
| 2025-10-06 | 22.58x |
| 2025-10-03 | 22.70x |
| 2025-10-02 | 22.52x |
| 2025-10-01 | 22.48x |
| 2025-09-30 | 21.38x |
| 2025-09-29 | 20.64x |
| 2025-09-26 | 20.55x |
| 2025-09-25 | 20.32x |
| 2025-09-24 | 20.68x |
| 2025-09-23 | 21.10x |
| 2025-09-22 | 21.21x |
| 2025-09-19 | 21.16x |
| 2025-09-18 | 21.40x |
| 2025-09-17 | 21.12x |
| 2025-09-16 | 21.13x |
| 2025-09-15 | 21.06x |
| 2025-09-12 | 21.16x |
| 2025-09-11 | 21.44x |
| 2025-09-10 | 20.89x |
| 2025-09-09 | 21.35x |
| 2025-09-08 | 21.20x |
| 2025-09-05 | 21.20x |
| 2025-09-04 | 20.91x |
| 2025-09-03 | 20.95x |
| 2025-09-02 | 20.88x |
| 2025-08-29 | 21.45x |
| 2025-08-28 | 21.28x |
| 2025-08-27 | 21.29x |
| 2025-08-26 | 21.20x |
| 2025-08-25 | 21.22x |
| 2025-08-22 | 21.47x |
| 2025-08-21 | 21.01x |
| 2025-08-20 | 21.54x |
| 2025-08-19 | 21.57x |
| 2025-08-18 | 21.58x |
| 2025-08-15 | 21.47x |
| 2025-08-14 | 21.33x |
| 2025-08-13 | 21.40x |
| 2025-08-12 | 21.06x |
| 2025-08-11 | 20.59x |
| 2025-08-08 | 20.58x |
| 2025-08-07 | 20.50x |
| 2025-08-06 | 20.39x |
| 2025-08-05 | 20.90x |
| 2025-08-04 | 20.81x |
| 2025-08-01 | 20.78x |
| 2025-07-31 | 21.05x |
| 2025-07-30 | 21.50x |
| 2025-07-29 | 21.74x |
| 2025-07-28 | 22.00x |
| 2025-07-25 | 22.11x |
| 2025-07-24 | 22.24x |
| 2025-07-23 | 21.72x |
| 2025-07-22 | 21.17x |
| 2025-07-21 | 18.45x |
| 2025-07-18 | 18.59x |
| 2025-07-17 | 18.80x |
| 2025-07-16 | 18.43x |
| 2025-07-15 | 18.35x |
| 2025-07-14 | 18.55x |
| 2025-07-11 | 18.76x |
| 2025-07-10 | 18.98x |
| 2025-07-09 | 18.70x |
| 2025-07-08 | 18.89x |
| 2025-07-07 | 18.73x |
| 2025-07-03 | 18.88x |
| 2025-07-02 | 18.91x |
| 2025-07-01 | 18.75x |
| 2025-06-30 | 18.34x |
| 2025-06-27 | 18.33x |
| 2025-06-26 | 18.39x |
| 2025-06-25 | 18.43x |
| 2025-06-24 | 18.42x |
| 2025-06-23 | 18.15x |
| 2025-06-20 | 18.12x |
| 2025-06-18 | 18.11x |
| 2025-06-17 | 18.07x |
| 2025-06-16 | 18.48x |
| 2025-06-13 | 18.29x |
| 2025-06-12 | 18.47x |
| 2025-06-11 | 18.44x |
| 2025-06-10 | 18.52x |
| 2025-06-09 | 18.07x |
| 2025-06-06 | 17.92x |
| 2025-06-05 | 17.53x |
| 2025-06-04 | 17.57x |
| 2025-06-03 | 17.16x |
| 2025-06-02 | 16.87x |
| 2025-05-30 | 16.96x |
| 2025-05-29 | 17.02x |
Showing the most recent 260 of 3,292 data points. The chart above shows the full history.
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib